Fendrix

BIOLOGICAL4 trials

Sponsors

Henogen, Dynavax Technologies Corporation, University of Surrey, Sheffield Teaching Hospitals NHS Foundation Trust

Conditions

Communicable DiseasesEnd Stage Renal DiseaseHBVHIVHealthyHepatitis BInfectious Diseases

Phase 2

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

CompletedNCT02434848

Sheffield Teaching Hospitals NHS Foundation TrustCommunicable Diseases, HBV, Hepatitis B +2

Start: 2015-07-23End: 2022-06-10Updated: 2022-09-29

Phase 3

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.

CompletedNCT00291941

HenogenHepatitis B

Start: 2006-02-28End: 2007-03-31Updated: 2008-08-28

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

CompletedNCT01195246

Dynavax Technologies CorporationEnd Stage Renal Disease

Start: 2010-12-31End: 2012-08-31Updated: 2019-03-20

Unknown Phase

Gene Expression Profiles in Muscle After Immunisation

CompletedNCT02368327

University of SurreyHealthy

Start: 2015-02-28End: 2015-07-31Target: 45Updated: 2015-08-10